General
Preferred name
Loracarbef
Synonyms
LORACARBEF HYDRATE ()
Loracarbef (hydrate) ()
LORACARBEF ANHYDROUS ()
Anhydrous loracarbef ()
Lorbef ()
LY-163892 ()
Loracarbef, anhydrous ()
Lorabid ()
Loracarbef monohydrate ()
LY-163892 MONOHYDRATE ()
LY163892 MONOHYDRATE ()
P&D ID
PD009114
CAS
76470-66-1
121961-22-6
Tags
available
covalent binder
drug
Approved by
FDA
First approval
1991
Drug indication
osteomyelitis
Bacterial infection
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Loracarbef is a second generation cephalosporin, belonging to the β-lactam class of antibacterial compounds.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
349.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
0.71
TPSA
112.73
Fraction CSP3
0.31
Chiral centers
3.0
Largest ring
6.0
QED
0.69
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Disease Area
infectious disease, otolaryngology, pulmonary
Indication
ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections
MOA
bacterial cell wall synthesis inhibitor
ATC
J01DC08
Target
antibiotic
Bacterial
Therapeutic Class
Antibiotics
Pathway
Anti-infection
Source data
